SyneuRx International (Taiwan) Corp. engages in developing drug for the treatment of unmet medical needs in central nervous system disorders in Taiwan.
The last earnings update was 96 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
SyneuRx International (Taiwan). This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
SyneuRx International (Taiwan)'s
is considered below, and whether this is a fair price.
Price based on past earnings
SyneuRx International (Taiwan)'s earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as SyneuRx International (Taiwan) has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
SyneuRx International (Taiwan)
expected to grow at an
Unable to compare SyneuRx International (Taiwan)'s earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare SyneuRx International (Taiwan)'s earnings growth to the Taiwan, Province of China market average as no estimate data is available.
Unable to compare SyneuRx International (Taiwan)'s revenue growth to the Taiwan, Province of China market average as no estimate data is available.
Unable to determine if SyneuRx International (Taiwan) is high growth as no earnings estimate data is available.
Unable to determine if SyneuRx International (Taiwan) is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
SyneuRx International (Taiwan)'s performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
SyneuRx International (Taiwan)
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
SyneuRx International (Taiwan)'s finances.
The net worth of a company is the difference between its assets and liabilities.
SyneuRx International (Taiwan) is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
SyneuRx International (Taiwan)'s cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
SyneuRx International (Taiwan)'s finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
SyneuRx International (Taiwan) has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
Guochuan Emil Tsai serves as Chairman and Chief Executive Officer of SyneuRx International (Taiwan) Corp. Guochuan Emil Tsai is an Assistant Professor at Harvard Medical School. Guochuan Emil Tsai is Professor of University of California, Los Angeles, School of Medicine. Guochuan Emil Tsai is Diplomate, American Board of Psychiatry and Neurology, both adult and child & adolescent Psychiat Guochuan Emil Tsai is Fellow of American College of Neuropsychopharmacology Guochuan Emil Tsai holds Ph.D. in Neuroscience from Johns Hopkins Medical School, USA and M.A.S. in Management from Johns Hopkins Business School, USA. Guochuan Emil Tsai is graduated from National Yang Ming University, School of Medicine.
Insufficient data for Guochuan to compare compensation growth.
Insufficient data for Guochuan to establish whether their remuneration is reasonable compared to companies of similar size in Taiwan, Province of China.
Chairman & Chief Executive Officer
Manager of Finance & Accounting
Board of Directors
Chairman & Chief Executive Officer
Wen Rui Huang
Who owns this company?
Recent Insider Trading
No 3 month open market individual insider trading information.
SyneuRx International (Taiwan) Corp. engages in developing drug for the treatment of unmet medical needs in central nervous system disorders in Taiwan. Its pipeline under clinical development includes SND-11, which is in Phase IIb/III clinical trial for the treatment of adolescent schizophrenia; SND-12 that is in Phase IIb/III clinical trial for combinational therapy on refractory schizophrenia; and SND-13, which is in Phase IIb/III clinical trial for the treatment of add-on therapy of schizophrenia. The company is also developing SND-14 for early dementia; SND-51 for dementia and psychosis symptoms; SNG-12 for the treatment of depression and suicidality; and SNA-1 to treat refractory major depression. SyneuRx International (Taiwan) Corp. was founded in 2013 and is based in New Taipei City, Taiwan.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.